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Abstract 
 
This thesis outlines the design and effectuation of novel chemical routes towards a 
nascent class of functionalised quinoline-5,8-diones and the expansion of a series of 
contemporary quinazolinediones towards an innovative family of 
pyridinoquinazolinetetrone derivatives. This fragment based approach is envisaged to 
lead to advancements in the three scaffolds, expanding the SAR pool of both quinolines 
and quinazolinediones with subsequent evaluation of chemotherapeutic potential as well 
as furnishing a new class of tricycle for biological investigation. 
Development of novel quinoline-5,8-diones is provided for by expanding on existing 
methodology. By using a variety of selected nucleophiles on a critical intermediate, a 
broad range of novel compounds was afforded which serve as molecular probes into the 
chemotherapeutic potency of this class of compounds, while also serving as integral 
intermediates for accomplishing novel pyridinoquinazolinetetrone congeners using 
contemporary cyclisation methodology. 
In order to incorporate functionality into our quinazolinedione template, an efficient 
synthetic strategy was constructed which provided a robust route to effectuate a highly 
derivatised pyrimidinedione ring from simple starting materials. As derivatisation of this 
template is unreported our chief priority was to synthesise a range of diverse 
quinazolinediones. The application of annulation methodology using functionalised 
precursors provided a library of N-3 derivatised quinazolinedione analogues. These, along 
with their N-1 functionalised derivatives provide a wide scope from which to construct a 
series of pyridinoquinazolinetetrone derivatives while also serving as a unique class of 
molecules whose biological potential is uncharted. 
Although the actualisation of the pyridinoquinazolinetetrone was ultimately unsuccessful, 
our work has led to the development of novel quinoline-5,8-diones which were found to 
possess excellent anti-cancer activity when assessed by the NCI screen. Preliminary results 
indicated appreciable cytotoxicity across several tumour types. 
  
vii 
  
Of the quinazolinediones synthesised eight compounds were accepted for screening by 
the NCI. Results from the single-dose tests however indicated that these compounds 
possessed little cytotoxic activity at 10 µM. The development of this novel template in 
conjunction with the highly active quinolinediones serves as an excellent rostrum for 
future synthetic endeavours. 
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1.0 Biological introduction 
 
The following chapter is divided into two sections based on the parent bicyclic fragment 
which pyridinoquinazolinetetrone 1 is derived from. Each section opens by briefly 
outlining the applications each pharmacophore has in medicinal chemistry followed by a 
detailed description of the biological profile of the scaffolds most relevant to this work. 
 
 
 
Fig 1.1.1 Illustrates both bicycles from which 1 is inferred. Highlighted in orange is the 
quinoline pharmacophore (Section 1.1) and the quinazoline fragment is highlighted in blue 
(Section 1.2). 
 
1.1 Quinolines 
 
The quinoline 2 scaffold which is comprised of a benzene ring fused with pyridine at two 
adjacent carbon atoms forms the foundation of a vast array of diverse compounds with 
extensive pharmacological properties. The quinoline structure is perhaps most notably 
associated with anti-malarial drugs arising from the isolation of the natural alkaloid 
quinine. Until the 1940’s it was the drug of choice for treatment of malaria until it was 
superseded by chloroquine, another quinoline, which possessed a more favourable 
pharmacological profile.1 
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Fig 1.1.2 
 
Due to much work being carried out on effective syntheses of quinoline compounds as 
well as diversification, a range of quinoline type compounds now possess among others, 
anti-tubercular,2 anti-hypertensive3 and anti-Alzheimer4 activity. Quinolines have also 
been shown to exhibit anti-cancer activity, highlighted in a recent review by Solomon et 
al..5 One subclass in the vast pedigree of quinolines which have received attention as 
antineoplastics in the last ten to fifteen years are quinoline-5,8-diones 3 due to their 
ability to inhibit Cdc25 phosphatase, a key regulator of the eukaryotic cell cycle, with some 
derivatives exhibiting nanomolar activity in in vitro assays.6 
 
 
Fig 1.1.3 
 
The following section outlines the role that quinoline-5,8-diones have in generating 
effective chemotherapeutic agents against Cdc25 phosphatase which has been shown to 
be overexpressed in a multitude of cancers, Table 1.1.1 (page 18). This focus stems from 
the direct relationship of 3 with the quinoline fragment of 1, Fig 1.1.1 (page 14). 
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1.1.1 Introduction to regulation of the cell cycle 
 
Common to all cancers is a disordered cell cycle and irregularities such as overexpression, 
deletion or mutations in the molecules which govern the cell cycle.7 A family of proteins 
known collectively as cell division cycle 25 (Cdc25) proteins are highly conserved dual 
specifity (acting on tyrosine or serine/threonine residues) phosphatases (DSP) which 
activate cyclin-dependant kinase (CdK) complexes, by dephosphorylating the Thr 14 and 
Tyr 15 residues of CdK. A consequent phosphorylation of Thr 161 by CdK-activating kinase 
(CAK) results in complete activation leading to cell-cycle progression Fig 1.1.5 (page 19).7,8 
Cdc25 phosphatases also play a role in checkpoint pathways, (e.g. G1/S or G2/M) which 
are activated as a result of DNA damage. When DNA damage occurs the cell responds by 
activating a relevant checkpoint mechanism, resulting in cell-cycle arrest which either 
leads to repair of the damaged DNA or apoptosis.9 Overexpression of Cdc25 is thought to 
lead to a loss of cell cycle checkpoint control, uncontrolled cell proliferation and a loss of 
genome integrity. From this it is easy to see that Cdc25 phosphatases make ideal targets 
for cancer therapy. 
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Cdc25A 
Cdc25C 
Cdc25B 
Cyclin E 
CDK2
P P 
Cyclin A 
CDK2
P P 
CDK1
P P 
Cyclin A 
 
Cyclin B 
CDK1
P P 
 
Fig. 1.1.4 Illustrates the four stages of the cell cycle. Thr 14 is represented as the yellow P 
and Tyr 15 is represented by the grey P. During the gap 1 (G1) phase (blue) cells increase 
in mass and synthesise mRNA and proteins for DNA synthesis. Synthesis (S) phase (brown) 
is where DNA synthesis occurs. Following completion of DNA replication the cell enters the 
gap 2 (G2) phase (grey) where cells continue to grow and synthesise proteins necessary 
for mitosis. The mitosis (M) phase, (yellow) involves cells duplicating into two identical 
cells.  
 
1.1.2 Cdc25 in cell-cycle control 
 
In the human genome three Cdc25 genes have been identified. These three isoforms are 
Cdc25A, Cdc25B and Cdc25C.10,11 Each gene can produce alternative splicing variants 
which generate two Cdc25A variants12 and five variants each for Cdc25B13,14 and 
Cdc25C.12,15 Of the three isoforms it is the overexpression of Cdc25A and Cdc25B which 
are linked to a variety of human malignancies in the majority of cases. Table 1.1.1 
illustrates the percentage of cancers which show the overexpression of Cdc25 proteins.9 
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Cancer type Cdc25 A %  Cdc25 B % Cdc25 C % 
Thyroid 17-69 36-64 ND 
Breast 70 57 ND 
Hepatocellular 56 20 ND 
Ovarian 30 30 ND 
Colorectal 47-53 43-67 27 
Non-Hodgkin lymphoma 50 65 15 
Gliomas ND 47 ND 
Laryngeal 41 57 ND 
Oesophageal 46-66 48-79 ND 
Gastric ND 78 ND 
Endometrial ND 73 13 
Prostate ND 30 ND 
 
Table 1.1.1 Percentage of tumours which exhibit overexpression of Cdc25A, Cdc25B or 
Cdc25C proteins, ND-not determined 9. 
 
Cdc25 proteins are responsible for activating CdKs which are a family of highly conserved 
serine/threonine protein kinases associated with regulatory cyclin subunits. CdKs are held 
in an inactive state by WEE1 and MYT1 kinases which phosphorylate the Thr14 and Tyr15 
residues of CdK1, located within the ATP binding loop of CdK.16 When CdK activity is 
necessary for the progression of the cell-cycle to the next phase the dual specifity 
phosphatases (Cdc25s) dephosphorylate both residues thereby activating the CdK-cyclin 
complex, Fig 1.1.5. CAK then phosphorylates Thr 161 yielding the fully active complex.8 
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Fig 1.1.5 Catalytic cycle of Cdc25 
 
In mammalian cells the three isoforms of Cdc25 are implicated in cell cycle regulation as 
a result of their ability to dephosphorylate CdK1 and CdK2. Although initially it was 
thought that there was a specific role for each Cdc25 phosphatase at defined stages of 
the cell cycle in reality it is emerging that all the Cdc25 isoforms are involved in 
phosphorylating CdK-cyclin complexes Fig 1.1.4 (page 17).9  
  
1.1.3 Structure and catalytic mechanism of Cdc25 phosphatase 
 
Cdc25 phosphatases are between 470 and 566 residues long and consist of two primary 
domains, an N-terminus and a C-terminus. The N-terminus contains a regulatory domain 
which modulates the activity of the enzyme. Contained within the C-terminus is the 
catalytic domain which is highly conserved among the three Cdc25 proteins.17 Within the 
catalytic domain is a phosphate binding loop (P-loop) also known as a HCX5R motif where 
H is a highly conserved histidine residue, C is the catalytic cysteine, X5 are the five residues 
which create the loop in which all amide nitrogens bond to the phosphate of the substrate 
and R is a highly conserved arginine which hydrogen bonds to the phosphorylated amino 
acid of the substrate,18 Fig 1.1.6. 
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Fig 1.1.6 Catalytic site P-loop bound to a tungstate anion19 
 
This motif is common to all tyrosine phosphatases. The structures of Cdc25A and Cdc25B 
have been solved by X-ray crystallography and showed similar catalytic domains.19,20 A 
key difference between these two isoforms is the relatively shallow active site of Cdc25A 
compared to Cdc25B whose active site is similar to other DSPs. The Cdc25A catalytic 
domain also contains no flexible peptide loops proximal to the active site that might 
facilitate substrate binding.   
 
Cdc25B contains a flat active site within a shallow pocket. Adjacent to the active site is a 
cavity known as the “swimming pool” due to the abundance of well-ordered water 
molecules contained within the pocket.21 The mechanism of catalysis occurs in two 
distinct steps.22 Firstly the catalytic cysteine acts as a nucleophile to the phosphate ester 
substrate, generating a thiophosphorylated intermediate. A proton transfer to the leaving 
group also occurs in this step however the origin of this proton is debatable. In other DSP 
proteins an Asp residue located in a mobile loop distal to the active site acts as the proton 
source (Cdc25s lack this catalytic site residue). The final step involves hydrolysis of the 
thiophosphorylated intermediate to regenerate the free enzyme as a free CdK-cyclin 
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complex which promotes cell cycle progression, Fig. 1.1.7. From this it is obvious to see 
that regulating this transfer would lead to control of the cell cycle. 
 
 
 
Fig. 1.1.7 Catalytic cycle of Cdc25B 
 
1.1.4 Inhibition of Cdc25 in anti-cancer therapy 
 
The main families of compounds which have been identified to be potent Cdc25 inhibitors 
include quinoline-5,8-diones, phosphomimetics and electrophilic entities.23 Quinoline-
5,8-dione compounds which are congeners of vitamin K are some of the most numerous 
and active compounds Fig. 1.1.8. 
 
 
Fig. 1.1.8 Illustrates the similarity between the vitamin K1 and quinoline-5,8-dione 
pharmacophores. 
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To date there has been no crystal structure of quinoline-5,8-diones docked in the Cdc25 
active site which hampers the establishment of a definite mechanism of action, however 
it is thought to involve either covalent adduct formation with a serine residue adjacent to 
the catalytic site,24 or irreversible oxidation of the cysteine residue in the catalytic domain 
to a sulphonic acid (Cys-SO3-).24 The two most potent compounds in this family are 
JUN1111 and its 6-chloro derivative NSC663284 (DA3003-1) which were synthesised by 
Lazo and co-workers.25,26 Adociaquinone B which is a derivative of a marine sponge extract 
also showed an excellent inhibition profile. Collaborative work between IPSEN 
pharmaceuticals and the research group of Boutros resulted in the discovery of two 
potent Cdc25 inhibitors, BN82685 and IRC083864, the latter displaying the most efficacy 
to date.9 Table 1.1.2 illustrates the nanomolar activity of the five most potent quinone 
derivatives against Cdc25 in an enzyme assay. Both BN82685 and IRC083864 were found 
to possess excellent inhibition properties against MiaPaCa2 (0.1 µM) and LNCaP (0.02 µM) 
cell lines respectively in vitro. Furthermore in vivo testing also showed encouraging results 
with both compounds showing activity against their respective cell lines in xenografted 
tumours in nude mice.  
 
Given the infancy of this research the selectivity of these compounds is an issue which 
requires future SAR development. It is envisaged that Cdc25 phosphatase inhibitors are 
not selective for tumour cell lines and would inhibit the cell-cycle progression of any cell 
type but the upregulation of Cdc25s in various cancers means increased sensitivity may 
exist. For example, both colon adenocarcinoma (HCT116) and pancreatic ductal 
adenocarcinoma show increased expression of Cdc25B and also show increased 
sensitivity to chemical inhibition of Cdc25 phosphatase activity.9,27 
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Compound Structure IC50 in vitro µM 
JUN1111 
 
0.38-1.8 
NSC663284  
(DA3003-1) 
 
0.2-0.9 
BN82685 
 
0.17-0.25 
Adociaquinone B 
 
0.07 
IRC083864 
 
0.02 
 
Table 1.1.2 In vitro IC50 values for five of the most potent compounds identified so far 
against the three Cdc25 isoforms. 
 
DA3003-1 was first reported by Lazo et al. in 2001 and showed sub micromolar inhibition 
of Cdc25, Fig. 1.1.9. Owing to the encouraging results from this study further elaboration 
of the pharmacophore was investigated by Wipf et al. in 2008.28 This study was based on 
inverting the six and seven positions of DA3003-1 type structures leading to the synthesis 
and biological evaluation of analogous quinoline-5,8-diones.  
 
Fig. 1.1.9 Inverse quinoline-5,8-diones WDP1079 and WDP1149 synthesised by Wipf et 
al..28 
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The IC50 values of WDP1079 and WDP1149 against the Cdc25B catalytic domain as well as 
subsequent cytotoxicity assays against the Cdc25B expressing lung cancer cell line A549 
are detailed below in Table 1.1.3. As a comparison the IC50 of DA3003-1 against A549 is 
also shown.24 Of the two quinolines synthesised by Wipf et al. it is apparent that 
halogenation of both the four and seven position results in greater activity against Cdc25B 
and A549. These encouraging preliminary findings provide the rationale to diversify this 
inchoate branch of quinolines and form the basis of our synthetic venture into quinoline-
5,8-diones as Cdc25 phosphatase inhibitors Section 6.2.1. 
 
Compound Cdc25B IC50 ± SEM/µM A549 IC50 ± SEM/µM 
DA3003-1 0.91 ± 0.36 1.48 ± 0.04 
WDP1079 1.10 ± 0.1 2.69 ± 0.08 
WDP1149 5.30 ± 0.6 9.52 ± 0.33 
 
Table 1.1.3 Comparison of in vitro efficacy of inverted quinoline-5,8-diones versus 
DA3003-1 against Cdc25B and human lung carcinoma cell line (A549). 
 
1.1.5 Conclusion 
 
The pivotal role CdKs play in cell cycle regulation makes them an attractive target for the 
ontogenesis of antineoplastic agents. As CdK activators, Cdc25 phosphatases are 
discernible targets for the development of novel approaches to indirectly inhibit CdKs and 
their ramifications on cell cycle regulation. The quinoline-5,8-dione pharmacophore 
represents a privileged template which serves as a molecular probe to investigate the 
consequence of Cdc25 phosphatase inhibition.  
To date, the exact role and mechanism of Cdc25 phosphatases remains vague largely due 
to the paucity of suitable exploratory templates, a niche where quinoline-5,8-diones 
apply. Given the importance of Cdc25 inhibition and its subsequent effects in cell cycle 
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control, the elaboration of the quinoline-5,8-dione pharmacophore is of eminent 
importance in order to expatiate the biological knowledge of this key process. 
 
1.2 Quinazolines 
 
The quinazoline scaffold, consisting of a core bicyclic structure 4, represents a family of 
molecules containing diverse pharmacophores which possess a broad spectrum of 
activity. Up until the late 1960’s, only two quinazolines were used medically, 
methaqualone 5, a soporific and anti-convulsant, and the diuretic quinethazone 6.29  
 
Fig 1.2.1 
However, in recent years there have been significant advances in this field leading to the 
generation of quinazoline derivatives possessing a range of activities including analgesic 
and anti-inflammatory, anti-malarial, anti-fungal, anti-diabetic, diuretic, anti-
hypertensive, sedative/soporific, anti-cancer as well as the treatment of benign prostatic 
hyperplasia.29 Between 2007 and 2010 alone eighty eight world patents were filed for 4-
anilinoquinazolines, a family of tyrosine kinase inhibitors which are at the forefront of 
chemotherapy.30 Our specific interest lies in the exploration of the quinazoline2,4-
(1H,3H)-dione scaffold 7 as they represent an underdeveloped domain of quinazolines.  
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1.2.1 Quinazoline-2,4-(1H,3H)-dione scaffold 
 
Quinazoline-2,4-(1H,3H)-diones 7 represent a branch of quinazoline derivatives which 
have also been found to possess a vast array of pharmacological properties ranging from 
serotonin receptor antagonists,31,32 glutamate receptor antagonists,33 α-adrenoceptor 
antagonists,34 acetylcholine receptor antagonists,35 anti-bacterial and anti-cancer 
agents.36-40 Owing to the intrinsic nature of quinazoline-2,4-(1H,3H)-dione fragment 7, Fig 
1.2.2, in pyridinoquinazolinetetrone 1, Fig 1.1.1 (page 14) the following section outlines 
the most prevalent biological applications of this pharmacophore.  
 
Fig 1.2.2 Structure and numbering sequence of quinazoline-2,4-(1H,3H)-dione. 
 
1.2.2 Anti-cancer activity 
 
A recently published paper by Zhou et al. documents the synthesis of a range of 
quinazoline-2,4-(1H,3H)-dione derivatives which were found to possess significant 
anticancer activity when tested against the NCI 60-cell line screen.40 Following SAR studies 
a total of forty-two relevant compounds were synthesised of which seventeen exhibited 
anti-proliferative activity. Four of these compounds were found to possess sub-
micromolar activity, Table 1.2.1 (page 27). The final two compounds (NSC D-752221/1 
and NSC D-751371/1) appear to have remarkable cytotoxic activity given their similarity 
to other compounds assayed. Due to the lack of selectivity of these compounds for a 
specific cancer sub-type, no plausible mechanism of action was identified, however these 
compounds may be useful as leads for future SAR studies. 
Chapter 1 | Biological Introduction 
 
Page | 27  
 
Compound % mean growth 
at 10 µM 
GI50 (µM) average 
value over 56 cell 
lines 
 
NSC D-750471/1 
20.39 0.794 
 
NSC D-752951/1 
14.59 0.741 
 
NSC D-752221/1 
-3.62 0.363 
 
NSC D-751371/1 
-81.75 0.407 
 
Table 1.2.1 The four most potent compounds synthesised by Zhou et al. when tested 
against the NCI 60-cell line screen. 
 
1.2.3 Geranylgeranyltransferase-I inhibitors 
 
Carrico et al. outlines the employment of quinazoline-2,4-dione congeners as perspective 
protein geranylgeranyltransferase-I (PGGTase-I) inhibitors as a potential 
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chemotherapeutic target.39 Geranylgeranyltransferase-I belongs to the prenyltransferase 
family which catalyse the lipidation of proteins. Specifically PGGTase-I catalyses the 
transfer of a geranylgeranyl moiety to the cysteine residue of specific proteins. PGGTase-
I is part of the CAAX prenyltransferase category where C is a cysteine residue, A represents 
any aliphatic amino acid moiety and X is leucine, isoleucine or phenylalanine. The 
precedence for this study is based on the fact that many PGGTase-I substrates were found 
to play a critical role in the development of tumours and subsequent metastasis. 
The PGGTase-I enzyme is a heterodimer with both α and β subunits containing primarily 
alpha helices, Fig 1.2.3.41 The α-subunit forms a crescent shape around the β-subunit. The 
β-subunit forms a compact, α–α barrel domain which contains a central cavity. At the α–
β interface is the substrate binding site which extends into the funnel-shaped cavity of the 
β-subunit. Contained along this funnel are hydrophobic residues with a catalytic zinc ion 
at the top of the funnel which binds to the cysteine of the CAAX system. 
 
Fig 1.2.3 PGGTase-I enzyme with the α- and β-subunits highlighted in red and blue 
respectively. The catalytic zinc is highlighted as the magenta sphere. Highlighted in cyan 
is 3’azaGGPP, a non-reactive analogue of geranylgeranyldiphosphate. Also shown in 
yellow is the CAAX (CVIL) residue of the peptide substrate.41 
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Design of peptidomimetics was based around the adaption of the CAAX residues.39 The 
central AA units were replaced with a rigid linker which lead to the synthesis of GGTI-2154 
a potent PGGTase-I inhibitor, IC50=21nM, Fig 1.2.4. The cysteine residue has also been 
replaced with an imidazole bioisostere which was previously shown to increase metabolic 
stability and selectivity for PGGTase-I. 
 
Fig 1.2.4 
To further this work, a series of molecular modelling studies were carried out in order to 
explore the development of novel PGGTase-I inhibitors, which revealed that the 
quinazoline-2,4-dione scaffold would be an attractive alternative to the biphenyl linker 
present in GGTI-2154. As a result a series of quinazoline-2,4-dione congeners were 
furnished in order to investigate their efficacy against PGGTase-I. Of the sixteen 
compounds two produced IC50 values in the nano-molar region, Fig 1.2.5. 
 
Fig 1.2.5 
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Comparison of derivatives 8 and 9 shows that the phenylalanine derivative 9 exhibits 
superior activity when compared to the leucine derivative 8. Further studies determined 
that an unsubstituted imidazole was necessary for effective binding to zinc. Conversion of 
the amino acid residues to the D-series lead to a complete drop off in activity most likely 
due to size restrictions in the X pocket. Docking studies of the leucine derivative 8 revealed 
that the compounds bind in the CVIL site suggesting the activity of these compounds may 
be due to competitive inhibition of PGGTase-I substrates. 
 
1.2.4 Anti-bacterial agents 
  
Quinazoline-2,4-(1H,3H)-diones have also been the subject of much interest as new 
avenues of therapy for resistant gram-positive infections.36,37 Fig. 1.2.6 (page 31) shows 
two of the existing antibiotics used in the treatment of gram-positive infections. The need 
to develop new therapies arises from the emergence of resistant strains of bacteria 
namely methicillin resistant Staphlococcus aureus (MRSA) and vancomycin resistant 
enterococci (VRE) which are of particular concern. There has also been an emergence of 
vancomycin resistant Staphylococcus aureus infection (VRSA), a drug which is usually 
associated as a last line therapy. Therefore it is easy to see the urgent need to develop 
original therapies to combat this serious clinical problem. 
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Fig. 1.2.6 Structures of ciprofloxacin and vancomycin. 
A study carried out by Huband et al. details the antibiotic activity of two novel quinazoline-
2,4-(1H,3H)-diones, PD 0305970 and the 3-desamino analogue PD 0326448 Fig. 1.2.7, 
which serve as next generation therapies for resistant and susceptible strains of 
bacteria.36 In vitro testing of the compounds was carried out against 1,036 clinically 
significant strains of bacteria. Both analogues were found to possess exceptional 
antibiotic activity versus gram-positive, including resistant strains. 
 
Fig 1.2.7 
The MIC90 values of PD 0305970 ranged from 0.008-0.5 µg/ml against staphylococci, 
streptococci, Corynebacterium spp., while PD 0326448 exhibited values which were two- 
to fourfold higher in an identical study. When compared against existing treatments for 
gram-positive resistant strains, Streptococcus pneumonia, Enterococcus faecalis, 
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Enterococcus faecium and staphylococci, PD 0305970 is bestowed with an exemplary 8- 
to 512-fold MIC90 advantage over existing treatments. 
The quinazoline-2,4-(1H,3H)-diones excel in the treatment of quinolone resistant mutants 
with similar or superior anti-bacterial properties as current quinolones to susceptible 
strains of gram-positive bacteria. A study using PD 0305970 showed that this activity is 
most likely due to the targeting of the gyrB and parE subunits in contrast to the quinolones 
which targets the gyrA and parC. 
In 2010 Oppegard et al. published work detailing the biological evaluation of novel 
quinazoline-2,4-(1H,3H)-diones as potential alternatives to quinolone type antibiotics.37 
In order to be viable these compounds had to fulfil two criteria; (i) possess activity against 
known quinolone-resistant mutants and (ii) to display similar activity as quinolone 
antibiotics towards DNA gyrase and Topoisomerase IV. It is thought that dual targeting 
agents assist in slowing the emergence of drug resistant mutants.  
In a previous study the same group demonstrated that gyrA and gyrB mutations of E. coli 
which are resistant to quinolone therapies displayed sensitivity to 8-methoxy-quinazoline-
2,4-diones. Both 8-methoxy and 8-methyl quinazoline-2,4-diones were then tested 
against three mutant gyrases in order to assess the efficacy of these compounds against 
high, moderate and low resistance strains, Table 1.2.2. 
As can be seen below both of the compounds show increased activity towards mutant 
strains relative to wild-type gyrase than ciprofloxacin, Table 1.2.2. Another study which 
examined these two compounds against the catalytic activity of S. aureus gyrase and S. 
aureus Topo IV demonstrated comparable efficacy which suggests that quinazoline-2,4-
diones may function as dual-target antibiotics. From these studies it can be seen that 
quinazoline-2,4-diones represent a class of drugs with promising potential in the fight 
against antibiotic resistance. 
 
Chapter 1 | Biological Introduction 
 
Page | 33  
 
 
 
Compound Wild-type 
gyrase IC50 
(µM) 
GyrA S83W 
gyrase IC50 
(µM) High 
GyrA G81C 
gyrase IC50 
(µM) 
Moderate 
GyrA A67S 
gyrase IC50 
(µM) Low 
Ciprofloxacin 0.45 ± 0.004 101 ± 1.9 28 ± 7.0 1.0 ± 0.15 
8-Methoxy 2.8 ± 0.1 5.9 ± 0.9 4.3 ± 0.4 2.4 ± 0.1 
8-Methyl 0.95 ± 0.15 3.8 ± 0.6 1.7 ± 0.2 1.2 ± 0.3 
 
Table 1.2.2 Inhibition of catalytic activities of E. coli gyrases 
 
1.2.5 Glutamate receptor antagonists 
 
Quinazoline-2,4-diones have also garnered attention as potential glutamate receptor 
antagonists. Glutamate (Glu) is the primary excitatory neurotransmitter in the central and 
peripheral nervous system and is involved in a range of physiological processes such as 
learning and memory. Excess glutamate transmission has also been implicated in a range 
of neurological disorders such as Alzheimer’s,42,43 Parkinson’s,44 epilepsy,45 multiple 
sclerosis46,47 as well as the transmission of pain.48-50 
Glutamate expends its effects by acting on two sets of receptors, metabotropic (mGluRs) 
and ionotropic (iGluRs) receptors. The ionotropic receptors are classified into three 
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subsets, N-methyl-D-aspartate (NMDA), α-Amino-3-hydroxy-5-methyl-4-
isoxazolepropionic acid (AMPA) and kainate (KA) receptors each of which contain six, four 
and five subunits respectively. While many insights have been provided by research into 
the role of NMDA and AMPA receptors, knowledge of the role of KA receptors is sparse 
owing to the lack of selective antagonists. 
Work carried out by Colotta et al. in 2004 detailed the synthesis of 3-hydroxy-1H-
quinazoline-2,4-diones and subsequent bioassays showed that these compounds were 
antagonistic towards NMDA and AMPA receptors.51 By manipulating the substituents on 
the quinazoline scaffold it was found that the affinity for a specific receptor type could be 
effected, Fig 1.2.8. 
 
Fig. 1.2.8 NMDA antagonist 7-chloro-3-hydroxy-1H-quinazoline-2,4-dione 10 and AMPA 
antagonist 7-chloro-3-hydroxy-6-(4H-1,2,4-triazol-4-yl)quinazoline-2,4(1H,3H)-dione 11. 
With this in mind the same group published a later paper exploring the SAR of this 
pharmacophore with the aim of developing KA specific antagonists to use as probes for 
the characterisation of the KA receptor.33 Diversification was investigated at the three and 
six positions, using the compounds in Fig 1.2.8 as lead compounds. Exploration of the 
three position was carried out on 7-chloro-3-hydroxy-1H-quinazoline-2,4-dione 10 with a 
variety of ethers being synthesised however these compounds lacked any affinity for 
AMPA, Gly/NMDA or KA receptors illustrating the necessity of the 3-hydroxyl group.  
Derivatisation of the six position led to the discovery of 6-(2-carboxybenzoylamino)-3-
hydroxy-1H-quinazoline-2,4-dione, 12, Fig 1.2.9. This compound exhibits a good affinity 
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for both high and low-affinity KA receptors with IC50 values of 0.62 and 1.6 µM 
respectively. The compound also shows good selectivity versus Gly/NMDA and AMPA 
receptors. Since few selective KA receptor antagonists are known, quinazoline-2,4-diones 
represent a family of compounds which are pivotal in the emergence of research in this 
field.  
 
Fig 1.2.9 
1.2.6 Conclusion 
 
The quinazoline-2,4-(1H,3H)-dione heterocycle represents a privileged pharmacophore 
with which to develop novel chemotherapeutic agents due to their widespread and 
distinct biopharmaceutical properties. The limited exploration of this moiety as 
antineoplastic agents has shown promising preliminary results, section 1.2.2, but much 
work is necessary in order to expound the mode of action of these drugs, congenerous to 
Carrico’s work on PGGTase-I inhibitors, section 1.2.3, so as to implement more judicious 
investigation.39  
Quinazolinedione derivatives have also been bequeathed with excellent anti-bacterial 
properties mediated by the inhibition of bacterial gyrase and topoisomerase IV and 
represent a new avenue in the treatment of multidrug and fluoroquinolone resistant 
strains of bacteria.  
Given the wide range of disorders implicated with excess glutamate transmission, 
antagonism of its receptors represents an attractive target for developing effective 
therapies. The quinazoline-2,4-(1H,3H)-dione scaffold represents an exemplary research 
tool in this field. Targeted elaboration of the quinazolinedione backbone conferred 
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remarkable selectivity profiles, leading to the generation of receptor specific antagonists. 
Owing to the sparsity of detailed knowledge of these receptors quinazoline-2,4-(1H,3H)-
diones serve as principle templates to expand the biological understanding of glutamate 
receptor antagonists. 
 
1.3 Perspectives 
In Sections 1.1 and 1.2 critical insight into the prevalence of both pharmacophores in 
medicinal chemistry was highlighted. The validated bioactivity of both classes of 
compounds proffers the paradigm of synthesising a tricyclic hybrid in the quest for novel 
chemotherapeutic agents. It is foreseen that the fusion of these structures to generate 
the unheralded pyridinoquinazolinetetrone 1 will lead to a cogent new template with 
which to pioneer new avenues of drug discovery. 
 
 
 
 
 
 
 
 
 
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
2.0 Quinoline Chemical Introduction 
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2.1 Introduction 
 
The quinoline moiety is of great interest to chemistry due to its prominence in biologically 
active natural products, in particular alkaloids, most notably as antimalarial drugs.52-54 
Perhaps the most known quinoline derivative is the alkaloid quinine, 13 which occurs 
naturally in the bark of the cinchona tree and was the antimalarial drug of choice from the 
17th century until the 1940’s. 
 
A wide range of quinoline derivatives display a broad range of pharmacological properties 
ranging from anti-cancer,55 anti-HIV,56 anti-hypertensive,57 anti-tuberculosis58 to anti-
Alzheimer activities.59 Due to their importance, continuing research is focused on the 
development of more efficient methods of synthesis as well as derivatisation. 
 
A key subset in the synthesis of quinolines are quinolones (hydroxyquinolines), in this 
chapter synthetic routes will be classified based on the substitution pattern of quinolones 
followed by the substitution pattern of quinolines; 
 2-Quinolones 
 4-Quinolones 
 Substituted quinolines 
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In each case syntheses will be classified based on the named reaction. The final section 
addresses the synthesis of quinoline-5,8-diones, a family of quinolines central to this 
work. 
 
2.2 Synthesis of 2-quinolones 
 
2.2.1 Knorr Synthesis 
 
The Knorr quinoline synthesis, first described in 1886 by Ludwig Knorr, is an 
intramolecular cyclisation reaction which converts a β-ketoanilide 14 to a 2-quinolone 15 
under strongly acidic conditions.60 The β-ketoanilide 14 is generated from the acid-
catalysed condensation of primary arylamines and β-ketoesters, Scheme 2.2.1.1. 
Scheme 2.2.1.1 
Recently, Klumpp et al. published an investigation into the mechanism of the cyclisation.61 
His results, supported by low-temperature 1H, 13C and 15N NMR indicated that the β-
ketoanilide 14 undergoes diprotonation at the two carbonyl oxygen atoms to form a 
distonic superelectrophile. Computational studies also showed that this conformation 
was the most stable, being at least 8 kcal mol-1 more stable than other dications. Klumpp 
synthesised a range of substituted 2-quinolones from acetoacetanilides (generated from 
the respective anilines and diketene) in the presence of trifluoromethanesulfonic (triflic) 
acid at ambient temperature in high to excellent yields for activated aryl groups e.g., 
Scheme 2.2.1.2.  
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Scheme 2.2.1.2 
This chemistry was unsuccessful for deactivated aryl groups with the exception of a para-
fluoro acetanilide which gave a moderate yield of 44 % (this was increased to 69 % with 
the addition of 10 mol % SbF5).  
Studies on acid equivalents were also performed, Scheme 2.2.1.3, where it was found that 
the yield decreased with decreasing quantities of triflic acid, in accordance with an earlier 
paper published by Staskun who observed that the Knorr cyclisation required heating with 
excess strong acid which is consistent with the formation of supercationic species.62 
 
 
Scheme 2.2.1.3 
 
 
 
 
Acid eq. Yield% 
25 97 
2.5 86 
1.0 0 
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2.3 Synthesis of 4-quinolones 
 
2.3.1 Conrad-Limpach synthesis 
 
The Conrad-Limpach synthesis, first described in 1891, involves the thermal or acid-
catalysed cyclisation of primary arylamines with β-ketoesters to generate the imine 16, 
which cyclises to 4-quinolone 17.63  
 
Scheme 2.3.1.1 
In a search for novel PDE4 inhibitors, Billah et al. employed this synthesis to yield the 8-
methoxyquinoline 18.64 o-Anisidine was condensed with ethyl 4,4,4-trifluoroacetoacetate 
in the presence of polyphosphoric acid to give the quinolone 19. Chlorination at the 4-
position generated 20 and subsequent catalytic dehydrogenation furnished the 8-
substituted quinoline 21. Bromination at the 5-position followed by carbonylation 
afforded 8-methoxyquinoline-5-carboxylic acid 22. Activation of the acid residue followed 
by reaction with the sodium salt of 4-amino-3,5-dichloropyridine gave 8-
methoxyquinoline-5-carboxamide 18, Scheme 2.3.1.2. Derivatisation of 18 in a 
subsequent publication resulted in the  synthesis of the dichloropyridine-N-oxide 
derivative.65 Both of these compounds showed very promising results as selective 
inhibitors of PDE4. 
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Scheme 2.3.1.2 
 
2.3.2 Camps Synthesis 
 
Li et al. used the Camps synthesis to synthesise a range of 6,7-substituted-2-phenyl-4-
quinolones 23 in a search for anticancer drug candidates due to the known anti-
microtubular activity of 2-phenyl-4-quinolones, which interact with tubulin at the 
colchicine (Figure 2.3.2.1) site.66 Access to these compounds was achieved via two 
synthetic routes. The first, Scheme 2.3.2.1, involves reacting o-amino acetophenones 24, 
and benzoyl chlorides 25 to form diarylamides 26. Potassium tert-butoxide mediated 
cyclisation of 26 resulted in the formation of 23.  
 
Chapter 2 | Quinoline Chemical Introduction 
 
Page | 44  
 
 
Scheme 2.3.2.1 
Li found that substitution at the 3’-position of 6,7-methylenedioxy derivatives is well 
tolerated with no significant change in activity for a range of electron-donating and 
electron-withdrawing substituents, the same was also true for steric bulk with OBz and H 
at the 3’-position showing similar results. 6-Amino derivatives (morpholine and 
pyrrolidine) showed high activity with IC50 values in the nano-molar range against tubulin 
polymerisation. Yields for the reactions ranged from 27-80% for a diverse range of 
substituents. All the compounds synthesised exhibited cytotoxic effects against a variety 
of human tumour cell lines including solid tumours. The most potent compound 
synthesised 27, Fig. 2.3.2.1, possessed GI50 values in the nano and subnanomolar range 
across the majority of cell lines tested in the NCI programme and is also a potent inhibitor 
of radiolabelled colchicine binding to tubulin with activity comparable to the anti-mitotic 
products colchicine, podophyllotoxin and combretastatin A-4. 
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Fig. 2.3.2.1 
The second method involves the acid catalysed condensation of substituted 
anthranilamides 28, with substituted acetophenones 29 to generate the corresponding 
imines 30. Lithium diisopropylamide mediated cyclisation of 30 gave the respective 2-
phenyl-4-quinolones 23 in good yields, Scheme 2.3.2.2. 
 
 
Scheme 2.3.2.2 
More recently Hadjeri et al. reported the synthesis and anti-mitotic activity of 5-hydroxy-
7-methoxy-2-phenyl-4-quinolones.67 The compounds were synthesised in a similar 
fashion to Scheme 2.3.2.2. In terms of structural requirements they found that a 7-
methoxy, a 5-hydroxyl group and a free N-1 were all necessary for anti-mitotic activity. 
The presence of a fluorine at the 3’- or 2’- position and a methoxy or chloro group at the 
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7-position resulted in high activity for cell cycle arrest and antiproliferation, with 31 being 
the most potent, Fig. 2.3.2.1. 
Sui et al. used the Camps synthesis to synthesise a series of novel quinolones 32 as 
potential topoisomerase II inhibitors.68 In all twenty-six compounds were synthesised and 
tested against topoisomerase II using ellipticine, as a reference. The most potent of the 
compounds synthesised was over 400 times more potent than ellipticine. 
 
Scheme 2.3.2.3 
Ketones 33 were synthesised by regioselective electrophilic aromatic substitution at the 
ortho position by the corresponding nitriles using titanium tetrachloride as catalyst. N-
Acylation of 33 using benzoyl chlorides under standard conditions gave the amides 34. 
Cyclisation of 34 under pressure in the presence of sodium ethoxide gave quinolones 35, 
which were demethylated using hydrogen bromide to yield quinolones 32, Scheme 
2.3.2.3.   
Buchwald et al. 69 developed a novel two-step synthesis of 2-aryl quinolones via a copper 
catalysed amidation of o-halophenones followed by a base catalysed Camps cyclisation of 
the resultant N-(2-ketophenyl)amides, Scheme 2.3.2.4. 
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Scheme 2.3.2.4 
From these findings a series of N-(2-ketophenyl)amides were synthesised in good yield. 
Cyclisation in the presence of 3-3.5 equivalents of base resulted in the generation of a 
library of 2-aryl (phenyl, chlorophenyl, pyridyl, thiophenyl and styryl) quinolones. 
 
2.4 Synthesis of substituted quinolines 
 
2.4.1 Combes synthesis 
 
The Combes synthesis of quinolines was first described in 1888 by the French chemist 
Alphonse-Edmund Combes.70 The reaction involves the acid catalysed condensation of 
ortho-unsubstituted anilines with β-diketones to generate 2,4-disubstituted quinolines, 
36, or β-keto aldehydes to give 4-substituted quinolines via an imine intermediate, 
Scheme 2.4.1.1. 
 
Scheme 2.4.1.1 
Though one of the less utilised cyclisation methods the Combes synthesis has found 
applications in the synthesis of benzoquinolines71,72 and pyrido[3,2’-b]carbazoles.73 
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2.4.2 Friedländer synthesis 
 
First described in 1882 by German chemist Paul Friedländer, the Friedländer reaction 
involves the condensation of o-aminoaryl aldehydes or ketones with an aldehyde or 
ketone possessing an α-CH2 group under basic or acidic conditions, Scheme 2.4.2.1. 
 
Scheme 2.4.2.1 
The Friedländer synthesis has the advantage of being one of the simplest and most 
straightforward methods for synthesising polysubstituted quinolines. The reaction is 
catalysed by both acid and base. Brønsted acids like sulfimic acid, hydrochloric acid, 
sulphuric acid, p-toluene sulfonic acid and phosphoric acid are widely reported as 
catalysts, though reaction conditions are usually harsh and lead to reduced efficiency and 
hence lower yields. Fehnel et al. reported that under thermal or base catalysed conditions 
simple ketones fail to react with o-aminobenzophenone.74  
A novel synthesis of 3-(methanesulfonyl)quinolines was developed by Atechian et al. as 
previous literature reported low to mediocre yields and long reaction times. Anthranilic 
acid 37 was firstly cyclised to benzoxazinone 38 followed by conversion to 3-
(methanesulfonyl)quinoline 39 in a 39% overall yield. The synthesis of 39 allowed access 
to derivatives at the 4-position. Chlorination of 39 using POCl3 and N,N-dimethyl-p-
toluidine in refluxing toluene for 7 hours gave 40, as a crystalline solid. Further 
derivatisation of 40 with secondary amines, like morpholine, gave 41 in an 80% yield. 
Elaboration of the 6-position of 41 was achieved using both Buchwald and Suzuki-Miyaura 
protocols to generate 42 and 43 in 78% and 56% yields respectively, Scheme 2.4.2.2.75 
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Scheme 2.4.2.2 
 
2.4.2.1 Lewis acid catalysed Friedländer synthesis 
 
Wu et al. published work detailing the use of molecular iodine as an efficient, mild and 
environmentally friendly catalyst in the Friedländer reaction.76 After screening several 
reaction conditions it was found that 1 mol% of iodine at room temperature for 16 hours 
produced a variety of 2,3,4-trisubstituted quinolines in good to excellent yields, Scheme 
2.4.2.1.1. The reaction was also shown to tolerate a wide range of ketones both cyclic and 
acyclic. 
 
Scheme 2.4.2.1.1 
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A similar study was carried out by Adapa and co-workers77 where neodymium(III) nitrate 
hexahydrate (5 mol%) was used as the Lewis acid catalyst for the reaction, Scheme 
2.4.2.1.1. This reaction, like Wu’s was applicable to a broad range of substrates, both 
cyclic and acyclic. 
In 2007, Atechian and co-workers75 published work detailing the synthesis of poly-
substituted quinolines via a gold(III)catalysed Friedländer synthesis first described by 
Arcadi et al.78 In this reaction the gold acts as a Lewis acid much like neodymium in 
Adapa’s synthesis, Scheme 2.4.2.1.1. The general reaction is outlined in Scheme 2.4.2.1.2.  
 
Scheme 2.4.2.1.2 
The condensation of 2-aminobenzophenones 44 with 45 led to the formation of 46 
however, if the carbonyl groups of 45 had similar reactivity a regioisomeric mixture was 
formed as was the case where R1= i-Bu/CH2OMe and R2= Me. The reaction proceeds 
smoothly giving moderate to good yields.  
 
2.4.2.2 Synthesis of quinolines from alcohols 
 
Ricardo and Yus developed an indirect Friedländer synthesis by reacting 2-aminobenzylic 
alcohols with a series of ketones.79 They proposed a metal free Meerwein-Ponndorf-
Verley reaction between 2-aminobenzylic alcohols and benzophenone using potassium 
tert-butoxide, followed by a Friedländer annulation to generate the quinoline. The 
mechanism was supported with deuterium labelling experiments and the fact that the 
reaction does not proceed in the absence of benzophenone. After optimisation using the 
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alcohol 47 and ketone 48 the desired quinoline 49 was isolated in a 99% yield, Scheme 
2.4.2.2.1. 
 
Scheme 2.4.2.2.1 
Expanding on this, a range of 2,3 and 4-tri-substituted quinolines were regioselectively 
synthesised in excellent yields, Scheme 2.4.2.2.2. 
 
Scheme 2.4.2.2.2 
 
2.4.2.3 Catalyst-free Friedländer annulation in water 
 
Wang et al. reported the synthesis of various quinolines from 2-aminobenzaldehyde 50 in 
aqueous conditions without the use of catalysts.80 A series of 2,3-disubstituted and 
polycyclic quinolines were synthesised in excellent yields, Scheme 2.4.2.3.1. This method 
is tolerant of a wide variety of substrates and is a useful, green addition to existing 
chemistry. 
 
Scheme 2.4.2.3.1 
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2.5 Pfitzinger synthesis of quinolines 
 
The Pfitzinger reaction involves the reaction of isatin 51 or its derivatives with methylene 
ketones in an alkaline medium to generate quinoline-4-carboxylic acid derivatives. The 
reaction was first described in 1886 by W. Pfitzinger and is the most important variant of 
the Friedlander synthesis.81 Isatin 51, in the presence of base is converted into an isatinic 
acid salt 52 which cyclocondenses via the α-keto function with methylene ketones. 
Treatment with acid results in the formation of quinoline-4-carboxylic acid derivatives 53, 
Scheme 2.5.1. 
 
Scheme 2.5.1 
Pfitzinger studied the reaction of isatin 51 with acetone in the presence of an aqueous 
base to generate 2-methyl-4-quinolinecarboxylic acid 54, Scheme 2.5.2. In further 
publications Pfitzinger reported optimised reaction conditions for the synthesis of 54 
using 33% NaOH at 100 °C for 8 hours giving up to an 80% yield while various other groups 
reported a drop in yield using more dilute sodium hydroxide solutions.82,83 
 
Scheme 2.5.2 
As is shown in Scheme 2.5.2 the reaction of 51 with symmetrical ketones results in the 
formation of only one product, similarly only one product is formed in the case of 
unsymmetrical ketones containing only one methyl/methylene group, Scheme 2.5.3. 
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Scheme 2.5.3 
Borsche et al.84 and Braun et al.85 carried out studies of unsymmetrical ketones (e.g. 
butanone) with 51 and found that 2,3-dimethyl-4-quinolinecarboxylic acid 55 was the 
major product with 2-ethyl-4-quinolinecarboxylic acid 56 being the minor. Palmer and 
McIntyre86 published a mechanism explaining these observations, Scheme 2.5.4. 
 
Scheme 2.5.4 
Buu-Hoi et al. demonstrated that 7-halogen-substituted isatins, when reacted with methyl 
ethyl ketone only give 2,3-dimethyl-8-haloquinoline acids.87,88 Generally the reactivity of 
carbanions for these reactions is 2°>1°>3° with the lack of 3° carbanion reactivity being 
due to steric restrictions. This rule is consistent with the findings of Palmer and McIntyre, 
Scheme 2.5.4.86 
Unsymmetrical ketones which contain aryl substituents were investigated by Palmer and 
McIntyre86, who found that the nature of the aryl substituent had an influence on the 
reaction products. Electron-withdrawing substituents at the para-position of the aryl 
group exclusively gave 3-aryl quinolinecarboxylic acids, 57. Unsubstituted or electron-
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donating groups at the para-position gave a mixture of compounds, 57 and 58 with the 
major product being 3-aryl quinolinecarboxylic acids, 57, Scheme 2.5.5.  
 
Scheme 2.5.5 
Synthesis of quinolinedicarboxylic acids from isatin 59 and its derivatives and α-keto acids 
is well documented in the literature, chiefly due to the search for anti-malarial drugs. 
Many groups studied the reaction of 59 and its derivatives with pyruvic acid to generate 
substituted quinoline dicarboxylic acids. Buchman and co-workers89 successfully 
synthesised 6,8-dichloroquinoline-2,4-dicarboxylic acid 60 in excellent yield using this 
protocol, Scheme 2.5.6. 
 
Scheme 2.5.6 
As can be seen in Scheme 2.5.6 the reaction conditions are quite mild. Cragoe 
demonstrated that when halo-substituted acids or their esters are used the reaction takes 
place even at room temperature, an example of which is shown in Scheme 2.5.7.90,91 
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Scheme 2.5.7 
The reaction of isatin 59 with chloropyruvic acid generated the dicarboxylic acid 61 which 
was decarboxylated in situ to give 62 in an 85% yield.92 
The reaction of isatin 51 with acetoacetic acid (β-keto acid) was investigated by Pfitzinger 
and structure 63 was proposed.83 Enhelhard later proved the structure of 63 by oxidation 
to 64, Scheme 2.5.8.93 
 
Scheme 2.5.8 
Alkyl aryl ketones are common reactants used in the Pfitzinger reaction and generate 2-
aryl quinoline-4-carboxylic acids exclusively.83 Similarly alkyl hetaryl ketones yield 2-
hetaryl quinolinecarboxylic acids. Due to the large number of publications only one 
example is shown, Scheme 2.5.9. Gilman94 and Atwell95 synthesised compounds of type 
65 in a search for anti-malarial drugs. 
 
Scheme 2.5.9 
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The Pfitzinger reaction provides a convenient method for the synthesis of polycyclic 
systems when cyclic ketones/diketones are used resulting in a wide variety of fused 
quinoline derivatives e.g., Scheme 2.5.10.96 
 
Scheme 2.5.10 
 
2.6 Skraup type synthesis  
 
The Skraup and Doebner-von Miller synthesis of quinolines involves the reaction of an 
aromatic amine containing at least one unsubstituted ortho-position with an electrophilic 
three carbon fragment. The archetypal Skraup synthesis involves the reaction of aniline 
with glycerol 66, sulphuric acid and nitrobenzene as an oxidising agent, although more 
recent non-organic oxidising agents such as arsenic pentoxide, boric acid, iron(III) salts 
and iodine have replaced nitrobenzene due to the reduction of resin formation, leading 
to purer isolates.97 The sulphuric acid acts to generate acrolein 67 in situ by catalysing the 
dehydration of 66 which then undergoes conjugate addition with aniline resulting in the 
formation of 68. Nitrobenzene then oxidises 68 to quinoline 69, Scheme 2.6.1. 
 
Scheme 2.6.1 
The Doebner-von Miller reaction is classically described as the reaction of aniline with the 
crotonic condensation product of an aldehyde or ketone, in this case acetaldehyde, 
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generating dihydroquinoline 70 and oxidation results in 2-methylquinoline 71, Scheme 
2.6.2. 
 
Scheme 2.6.2 
Due to the low-yielding nature of the Skraup and Doebner-von Miller syntheses, recent 
investigations have been devoted to finding optimal reaction conditions. Li et al. used a 
system of 12 M HCl, toluene and tetrabutylammonium chloride when synthesising 2-alkyl-
8-quinolinecarboxylic acid which gave a 57% yield.98 Matsugi et al. also reported improved 
yields by using a mixture of 6M HCl and toluene in their syntheses.99 
 
2.6.1 Substituent effects on cyclisation 
 
Aromatic amines substituted at the ortho-position lead to the formation of 8-substituted 
quinolines, Scheme 2.6.1.1.100 
 
Scheme 2.6.1.1 
para-Substituted aminobenzenes cyclise at any symmetrical ortho-position to give 6-
substituted quinolines. 2,5-Dimethyl-4-(p-nitrobenzyl)pyridine 72 was reacted under 
Skraup conditions to generate 6-[(2,5-dimethyl-4-pyridyl)methyl]quinoline 73. 2,5-
Dimethyl-4-(p-nitrobenzyl)pyridine  74 from which 72 was synthesised also acted as the 
oxidising agent, Scheme 2.6.1.2.101 
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Scheme 2.6.1.2 
meta-Substituted anilines, 75 cyclise to give a mixture of 5 and 7 substituted quinolines 
with the outcome dependant on the substituent at the meta position.  
Strong electron-donating substituents preferentially give 7-substituted quinolines, 76 
(78:22). Weaker electron-donating substituents also give 7-substituted quinolines with 
only a slight preference however (56:44). Strong electron-withdrawing groups promote 
cyclisation at the 2-position of 75 giving 5-substituted quinolines, 77 as the main product 
(78:22), Scheme 2.6.1.3.102-108  
 
Scheme 2.6.1.3 
 
 
2.7 Quinoline-5,8-diones 
 
Central to this project is the synthesis of novel quinoline-5,8-diones. Interest in this family 
of compounds as antineoplastics arose from a study carried out in 2001 by Lazo and co-
workers.6 The search for novel inhibitors of Cdc25 in the NCI repository lead to the 
identification of 30 quinolinediones, of which 8 had micromolar activity. Outlined in 
Scheme 2.7.1 is the synthetic route used by Lazo to access quinoline-5,8-diones using 
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syntheses previously described.109-111 Oxidation and chlorination of quinoline-8-ol 78 was 
achieved in one step to generate 79 in a 30% yield. Amination of 79 was carried out at 
ambient temperature using functionalised ethyl amines in the presence of triethylamine, 
leading to the synthesis of a mixture of regioisomers 80 (DA3003-1) and 81 (DA3003-2) in 
a 2:1 mixture (measured by NMR) which were separated using column chromatography. 
 
Scheme 2.7.1 
More recently Wipf et al. published work detailing the synthesis of compounds of type 81 
in an effort to address the problems associated with quinoline-5,8-dione redox cycling 
leading to undesired off-target mechanisms. Synthesis starts from 2,5-dimethoxyaniline 
82 which is refluxed with Meldrum’s acid and trimethyl orthoformate resulting in the 
formation of 83 in an 80% yield. Bromination of 83 at the four-position was achieved using 
a mixture of bromine and acetic acid to afford 84 in an 84% yield. Pyridone 85 is realised 
in an 81% yield by refluxing 84 in diphenyl ether at 250 °C. Treatment of 85 with POCl3 
results in the formation of the 4-chloroquinoline 86. Synthesis of the desired quinoline-
5,8-diones was carried out in a two-step process. Firstly 86 is oxidatively demethylated 
using ceric ammonium nitrate. Following completion the isolated crude product is 
aminated at the 6-position using 4-(2-aminoethyl)morpholine to afford the functionalised 
quinone 87. Finally chlorination of the 7-position was achieved by treating a methanolic 
solution of 87 with N-chlorosuccinimide to generate WDP1079 in a 65% yield, Scheme 
2.7.2.28 
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Scheme 2.7.2 
Wipf also used this synthesis to generate the 4-methoxy-7-fluoro derivative of WDP1079, 
WDP1149. Generation of the methyl ether was afforded by heating 86 with sodium 
methoxide in methanol to generate 88. Synthesis of the 6-amino quinoline was achieved 
using analogous conditions to Scheme 2.7.2. Fluorination of the 7-position was achieved 
using Selectfluor® to afford WDP1149 albeit in low yield, Scheme 2.7.3.28 
 
 
Scheme 2.7.3 
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2.8 Conclusion 
 
Due to their widespread applications in medicinal chemistry considerable progress has 
been made in the development of the efficient synthesis of the quinoline pharmacophore. 
While traditional methods remain firmly rooted in many syntheses, pullulating biological 
interest has led to the genesis of numerous novel methodologies which offer highly 
derivatised quinolines from simple precursors. 
Given the promising preliminary biological results attributed to quinoline-5,8-diones this 
family of compounds make an attractive synthetic target. The sum total of literature in 
this area is outlined in Section 2.7 making it obvious that the scope for development of 
this area is tremendous. With the importance of their application highlighted in Section 
1.1.4 development of this pharmacophore is imperative in order to elucidate their mode 
of action and ameliorate this area of medicinal chemistry. 
  
 
 
 
 
 
 
 
3.0 Quinazoline Chemical 
Introduction
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3.1 Quinazoline introduction 
 
Quinazolines 89, Scheme 3.1.1 and their related derivatives can be found embedded in a 
wide range of biologically active compounds, for example, anti-cancer, anti-fungal, 
diuretic, anti-inflammatory, anti-convulsant and anti-hypertensive drugs.112-115 This class 
of compound forms a substantial part of heterocyclic chemistry and is of considerable 
interest to the pharmaceutical industry. 
 
Scheme 3.1.1 
The first quinazoline-based alkaloid natural product, vasicine (peganine) 90, Scheme 3.1.1 
was isolated from the plant material of Adhatoda vasica in 1888.116 Research remained 
dormant until the 1950’s when the effectiveness of quinazoline derivatives as anti-
bacterial, anti-viral and anti-parasitic agents were discovered.117 It has only been the last 
fifteen years that research has seen significant advances, which is driven by their diverse 
applications. 
 
Many literature syntheses of quinazolines require long reaction times and are often low 
yielding.118-120 As a result much attention has been focussed to develop more efficient 
methods for the construction of quinazolines. Although in the majority of cases no new 
chemistry was employed, the use of microwave-enhanced processes and new catalysts 
offer clear advantages both in yield and reaction time.  
 
In this chapter synthetic routes will be classified based on the increasing substitution 
patterns of the pyrimidine ring system converging on syntheses most relevant to this 
work; 
 2-Substituted quinazolines 
 4-Substituted quinazolines 
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 2,4-Disubstituted quinazolines 
 Quinazoline-2,4-diones 
 N-3 Substituted quinazoline-2,4-diones 
 N-1, N-3 Substituted quinazoline-2,4-diones   
 
3.2 Synthesis of 2-substituted quinazolines 
 
2-Substituted quinazolines represent a medicinally important branch of quinazolines, 
finding uses in the treatment of essential thrombocytosis, chronic myeloid leukaemia, 
hypertension and heart disease. Anagrelide is used in the treatment of essential 
thrombocytosis (overproduction of blood platelets) and has also been used for treating 
chronic myeloid leukaemia.121 Its congener, quazinone is a PDE3 inhibitor used for the 
treatment of heart disease. Quinethazone is a thiazide-type diuretic used in the treatment 
of hypertension,122 Fig. 3.2.1. 
 
 
Fig. 3.2.1 
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3.2.1 Synthesis from triazoline intermediates 
 
In 1999 Erba and co-workers published a method for the synthesis of 2-alkylquinazolines 
from triazolines, Scheme 3.2.1.1.123 Synthesis of the triazoline intermediates began by 
reacting a functionalised aldehyde with morpholine in toluene at room temperature to 
generate the enamine 91 and subsequent reaction with an aryl azide to generate 
triazoline 92.  
Cyclisation to 2-alkylquinazolines 93 was afforded by treatment of 92 with either a 
saturated ethanolic solution of ammonia at 150 °C, or in ammonium acetate in refluxing 
toluene. Yields for this reaction varied from excellent 93a (92%) and 93b (95%) to 
moderate for 93c (38%) and 93d (37%). Overall this synthesis proved to be a robust and 
reliable method for the synthesis of 2-substituted quinazolines that possess electron-
withdrawing groups at the 6-position. 
 
Scheme 3.2.1.1 
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3.2.2 Reaction of amidines with 2-fluorobenzaldehydes 
 
In 1999 Kotsuki et al. published their work on the reaction of cyano/nitro activated o-
fluorobenzaldehydes with a variety of arylamidines to generate 2-aryl quinazolines in 
moderate yields after chromatography, Scheme 3.2.2.1.124 The reaction involves the 
condensation of o-fluorobenzaldehydes 94 with aryl amidines resulting in the formation 
of imines 95 followed by a nucleophilic aromatic substitution at the ortho-position in the 
presence of potassium carbonate in acetonitrile at reflux to generate quinazolines 96.  
 
Scheme 3.2.2.1 
 
3.3 Synthesis of 4-substituted quinazolines 
 
Some of the most promising 4-substituted quinazolines synthesised to date are shown in 
Fig. 3.3.1. In 2003 Iressa™ was the first epidermal growth factor receptor inhibitor, for the 
treatment of lung cancer.113 Similar compounds such as afatinib and dacomitinib are 
currently undergoing phase III clinical trials, Fig 3.3.1. The prevalence of this family of 
compounds in chemotherapy was previously highlighted in Section 1.2. 
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Fig. 3.3.1 
3.3.1 Derivatisation of 4(3H)-quinazolinones 
 
Conversion of 4(3H)-quinazolinones to 4-chloroquinazolines is well documented in the 
literature and is most commonly achieved by treating a quinazolin-4-one with POCl3 or 
thionyl chloride.125-127 An alternative synthesis was published by Sugimoto et al.  which 
involves the use of a phosphonium salt of N-chlorosuccinimide, 97 in refluxing dioxane to 
give good yields of 4-chloroquinazolines, 98, Scheme 3.3.1.1.128 4-Chloroquinazolines are 
very versatile intermediates as they can be derivatised further through nucleophilic attack 
at the C-4 position. 
 
Scheme 3.3.1.1 
Chapter 3 | Quinazoline Chemical Introduction 
 
Page | 70  
 
The 4-position can also be activated using a thiomethyl substituent as reported by 
Rewcastle et al.126 Treatment of  quinazolinone 99 with Lawesson’s reagent affords 
quinazolinethione, 100 which is converted to the thiomethyl ether 101 by treatment with 
potassium hydroxide and iodomethane. Displacement of the thioether with a nucleophile 
affords the 4-substituted quinazoline 102, in good yield, Scheme 3.3.1.2. 4-
Arylaminoquinazolines are of particular interest due to their potential as antitumour 
agents, Scheme 3.3.2.2.113 
 
Scheme 3.3.1.2 
As well as useful intermediates 4-thioquinazolines also garnered some attention as 
potential antifungal agents. Xu and co-workers synthesised a range of 6-fluoro-4-
alkylthioquinazolines with derivatives containing 4-thioallyl, 4-thio-n-propyl and 4-
thioethyl showing good antifungal activity.129 Synthesis began by reacting 2-amino-5-
fluorobenzoic acid 103 with formamide to generate the quinazolinone 104. Thiol 105 was 
afforded from treatment of 104 with Lawesson’s reagent. Alkylthioquinazolines 106 were 
synthesised in good to excellent yield by treating 105 with a number of alkyl halides under 
phase-transfer conditions, Scheme 3.3.1.3.  
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Scheme 3.3.1.3 
 
3.3.2 Reaction of anilines with 2-aminobenzonitrile 
 
4-Anilinoquinazolines can also be synthesised from the reaction of 2-aminobenzonitrile 
107 and anilines 108 as detailed by Szczepankiewicz et al.130,131 These reactions proceed 
via amidines 109 which are heated with 85% formic acid to give 4-arylaminoquinazolines 
110 in good yields, Scheme 3.3.2.1. 
 
Scheme 3.3.2.1 
 
Compounds of similar structure were reported by Foote et al. which exhibited anti-
tumour activity, 111, Fig. 3.3.2.2.132 Vasdev and co-workers published work on 18F labelled 
4-anilinoquinazolines as potential EGFR imaging probes, 112, Fig. 3.3.2.2.133  
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4-Anilinoquinazolines have also been studied as potential tyrosine kinase inhibitors by 
pharmaceutical companies, AstraZeneca134 and Qilu, 113, Fig. 3.3.2.2.135,136 
 
Fig. 3.3.2.2 
Tsou et al. reported an efficient method for the synthesis of 4-anilinoquinazolines where 
incorporation of the 4-anilino group and ring closure were achieved in one step.137 The 
first step of the reaction involved the condensation of 2-amino-5-nitrobenzonitrile 114 
with DMF dimethylacetal. Refluxing the resultant imine 115 in acetic acid with 3-
bromoaniline gave the desired compound 116 in an 89% yield, Scheme 3.3.2.3. A similar 
method was reported by Yoon et al. using microwave conditions to generate substituted 
4-aminoquinazolines in excellent yield.138 
 
Scheme 3.3.2.3 
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3.3.3 Palladium mediated quinazoline synthesis 
 
A novel method for synthesising 4-substituted quinazolines involving a palladium 
catalysed reaction was developed by Akazome et al.139 The reaction involves an 
intermolecular reductive N-heterocyclisation between 2-nitrophenyl ketones 117 and 
formamide to give a variety of 4-substituted quinazolines 118, Scheme 3.3.3.1. It was 
speculated by the authors that the reaction proceeds via an active nitrene intermediate 
which was generated by selective deoxygenation of the nitro group by carbon monoxide. 
 
Scheme 3.3.3.1 
 
3.4 Synthesis of 2,4-disubstituted quinazolines 
 
There are many examples of 2,4-disubstituted quinazolines in medicine, three of which 
are highlighted in Fig. 3.4.1. Bunazosin was initially developed to treat benign prostatic 
hyperplasia.140 Its congener prazosin is an alpha-adrenergic antagonist used for the 
treatment of high blood pressure, anxiety and panic disorder.141 Linagliptin is a 2,4-
disubstituted quinazoline which was approved in 2011 for the treatment of type-II 
diabetes, which acts by inhibiting DPP-4.142  
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Fig. 3.4.1 
 
3.4.1 Reactivity of 2,4-dichloroquinazolines 
 
As was mentioned in Section 3.3.1, chloroquinazolines serve as useful intermediates when 
derivatising quinazolines. 2,4-Dichloroquinazolines can be accessed in good yields from 
chlorinating the corresponding quinazoline-2,4-dione using phosphorous oxychloride or 
thionyl chloride. Due to the increased electrophilicity of the 4-position, regiospecific 
substitution can be achieved by nucleophilic substitution. Lee et al.  exploited this 
regioselectivity in the synthesis of potential phosphodiesterase inhibitors, Scheme 
3.4.1.1.143 
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Scheme 3.4.1.1 
Quinazoline-2,4-dione 119 was prepared from anthranilamide using phosgene or 
anthranilic acid using potassium isocyanate followed by cyclisation. 2,4-
Dichloroquinazoline 120 was furnished by refluxing 119 in POCl3. The 4-position was then 
selectively aminated using benzylamine. An imidazole moiety was subsequently 
introduced at the 2-position by heating 121 with excess imidazole to give 122 in a 63% 
yield. The inherent reactivity of both the 2 and 4 positions allows expansive diversification 
of the quinazoline pharmacophore in a regioselective manner.  
Undheim et al. investigated the use of trialkylalanes in palladium catalysed coupling 
reactions, Fig. 3.4.1.2.144 Synthesis of 2-chloro-4-methylquinazoline, 123 is achieved in a 
76% yield. The mechanism involves the oxidative addition at the more electrophilic 4-
position of 120 to the palladium (0) complex. The methyl group is transferred to the 
palladium (II) complex from the aluminium and subsequent reductive elimination 
generates 123 in good yield. Repeating the process using tri-isobutylalane affords 2-
isobutyl-4-methylquinoline, 124 in an 80% yield. This method provides a regiospecific 
route to bioactive 2,4-disubstituted quinazolines. 
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Fig. 3.4.1.2 
 
3.4.2 Chlorination of quinazoline-2,4-dione in the presence of cyclic amines 
 
As was alluded to in Section 3.4.1 the 4-position of 120 is more reactive towards 
nucleophiles than the 2-position.  Based on work initially carried out by Miki, Yoshida et 
al. published work which demonstrated that the 2-position could be selectively 
substituted using a tertiary cyclic amine in the presence of POCl3 in good yield.145,146 This 
work was conducted while developing a more frugal route to the potential anti-dementia 
drug, 2-(4’-allylpiperazin-1-yl)-4-pentyloxyquinazoline. Reaction of quinazoline-2,4-dione 
119 and 1,4-diallylpiperazine 125 afforded the key intermediate, 2-(4’-allylpiperazin-1-yl)-
4-chloroquinazoline 126, Scheme 3.4.2.1. If a primary or secondary amine is used in place 
of a tertiary the reaction proceeds typically with substitution occurring at the more 
favoured 4-position.118 
 
Scheme 3.4.2.1 
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3.4.3 Synthesis of 2,4-diaminoquinazolines 
 
Zielenski et al. reported the synthesis of 2,4-diaminoquinazolines from chloroamidines 
and dialkylcyanamides.147 The chloroamidines were synthesised in two steps from 
substituted phenyl isocyanates via reaction with N,N-diethylamine to afford substituted 
ureas. Treatment with phosphorous pentachloride generated the chloroamidines 127. 
Reaction with N,N-dimethylcyanamide followed by cyclisation furnished 2,4-
diaminoquinazolines 128, Scheme 3.4.3.1. Although a wide variety of substituted 
phenylisocyanates were tolerated, purification of the quinazolines proved difficult in 
some cases leading to lower yields. 
 
Scheme 3.4.3.1 
Wilson et al. reported the synthesis of 2,4-disubstituted quinazolines using a resin bound 
isothiocyanate 129 generated from the parent carboxystyrene resin. Their investigation 
began with the synthesis of the antihypertensive drug prazosin, which was achieved in 
three steps from 129. 2-Amino-4,5-dimethoxybenzonitrile was dissolved in NMP, added 
to the resin and stirred for 3 hours to generate 130. Treatment of the intermediate with 
1-(2-furoyl)-piperazine and EDC under basic conditions to furnish the resin bound 
guanidine 131. Cleavage and cyclisation was achieved using a mixture of trifluoroacetic 
acid and water yielding prosazin 132 as the TFA salt in a 24% overall yield, Scheme 
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3.4.3.2.148 This method offers an alternative to sequential chlorine displacement of 2,4-
dichloroquinazolines employed by Lee et al..143 
Scheme 3.4.3.2 
 
3.4.4 Rearrangement of triazolines to 2-alkyl-4-arylaminoquinazolines 
 
Previous to his work on 2-substituted quinazolines (Scheme 3.2.1.1) Erba et al. reported 
the synthesis of 2-alkyl-4-anilinoquinazolines via the cyclisation of arylamines with 
amidines. Refluxing triazoline 133 in xylene induces thermal elimination of nitrogen 
followed by rearrangement to the tertiary amidine 134. Reaction of 134 with anilines 
afforded a range of 2-alkyl-4-anilinoquinazolines 135 in moderate to low yields, Scheme 
3.4.4.1.149 The low yields of 135d and 135e, which could not be improved upon with 
longer reaction times, is due to the lower nucleophilicity of the substituted arylamines 
used for the cyclisation. Conversely 135c shows a higher yield due to the increased 
nucleophilicity of the aryl substituent. It also seems that the steric bulk of the R group 
influences yields, which is illustrated when comparing 135a and 135b.  
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Scheme 3.4.4.1 
 
3.4.5 Microwave synthesis of 2-substituted-4-aminoquinazolines 
 
The synthesis of 2-substituted-4-aminoquinazolines was reported by Seijas and co-
workers in 2000.150 2-Aminobenzonitrile 136 was reacted with a variety of nitriles in the 
presence of potassium tert-butoxide under microwave conditions to give quinazolines 137 
in excellent yield, Scheme 3.4.5.1. These reactions represent a significant improvement in 
methodology not only because of their short reaction time but improved yields, catalytic 
amount of base and absence of solvent. 
 
Scheme 3.4.5.1 
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3.4.6 Use of Grignard reagents 
 
Bergman et al. demonstrated that when 2-aminobenzonitrile is reacted with Grignard 
reagents the resulting intermediate was useful in accessing a variety of quinazoline 
derivatives in good to excellent yields, when quenched with suitable electrophiles (acid 
chlorides, formates, oxalates and Viehe’s salt).151,152 It was found that when quenched 
with diethyl oxalate the quinazoline product generated was susceptible to reaction with 
a second mole of the intermediate leading to the formation of 2,2’-coupled bis-
quinazoline, accounting for the lower yield of the desired product. This general approach 
for synthesis of 2,4-disubstituted quinazolines is a useful addition to existing procedures, 
given the range of available Grignard reagents, Scheme 3.4.6.1.  
 
Scheme 3.4.6.1 
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3.5 Synthesis of Quinazoline-2,4-diones 
 
There are many examples of this reaction type in the literature.40 Some of the more recent 
publications are discussed below which detail more bespoke preparations that display 
clear advantages over conventional methods. 
3.5.1 Quinazoline-2,4-diones from aminobenzonitrile precursors 
 
Mizuno et al.  first described the synthesis of quinazoline-2,4-diones in 2000 using 2-
aminobenzonitrile 138 and carbon dioxide in the presence of DBU, Scheme 3.5.1.1.153 
More recently the same group used supercritical carbon dioxide in place of organic 
solvents to synthesise a range of quinazoline-2,4-diones 138 in good to excellent yields.154 
Gao et al. published similar work detailing the use of guanidines as catalysts for this 
reaction with very encouraging results.155 Skibo and Sung published work which included 
more conventional methods where an anthranilamide is treated with phosgene to 
generate compounds of type 139. The preceding anthranilic acid can also be cyclised 
directly upon treatment with potassium isocyanate, Scheme 3.4.1.1.156,157 
 
Scheme 3.5.1.1 
 
3.6 N-3 substituted quinazolinediones 
 
The application of N-3 substituted quinazolinediones has been previously discussed in 
Section 1.2.2, which highlights the promising anti-cancer activity of some recently 
described N-3 substituted quinazolinediones. 
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3.6.1 Baeyer-Villiger oxidation to 3-arylquinazoline-2,4-diones 
 
Azizian et al. described the synthesis of 3-arylquinazoline-2,4-diones via the 
rearrangement of benzoxazinones.158 The procedure involves the oxidation of 3-
arylimino-2-indolinones 140 with m-chloroperbenzoic acid at 0 °C to generate 141. The 
expected quinazolinedione 142 was formed in excellent yield after separation from 
impurities by flash chromatography, Scheme 3.6.1.1. A range of quinazolinediones were 
synthesised demonstrating the versatility of this procedure. When the reaction was 
carried out in methanol it was found that the carbamate, 143 was returned in high yield. 
Cyclisation of 143 to the corresponding quinazolinedione 142 was afforded by heating 143 
to its melting point. 
 
Scheme 3.6.1.1 
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3.6.2 Preparation using Appel’s salt 
 
Kim et al. developed a facile synthesis of a range of 3-substituted-2-cyano-4(3H)-
quinazolinones. Reaction of methyl anthranilate  144 with Appel’s salt 145 in the presence 
of pyridine returned dithiazolium 146 in a 50% yield.159 3-Substituted-2-cyano-4(3H)-
quinazolinones 147 are afforded by reacting primary alkylamines with dithiazolium 146. 
The nitrile group can readily be displaced by a variety of nucleophiles to generate a range 
of corresponding 2-substituted analogues. Hydrolysis of the nitrile offers a convenient 
method for synthesising N-3 substituted quinazolinediones 148 in moderate to good 
yields (R=Me, 56% overall), Scheme 3.6.2.1.  
 
Scheme 3.6.2.1 
 
3.6.3 Palladium-catalysed synthesis of N-3 substituted quinazoline-2,4-diones 
 
Willis et al.  developed an efficient synthesis of N-3 substituted quinazolinediones 148 by 
reacting methyl o-bromobenzoate 149 with mono-N-substituted ureas 150 in the 
presence of a palladium catalyst, Scheme 3.6.3.1.160 This method is tolerant of a wide 
variety of substituted ureas as well as both electron-donating and electron-withdrawing 
substituents on the benzene ring of 149. Regioselectivity was determined by comparison 
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with existing literature, 2D NMR studies and conversion to known compounds. Willis 
speculated that selectivity is due to an initial arylation reaction followed by a ring-closing 
amidation reaction, with the arylation occurring at the least hindered nitrogen of the urea. 
 
Scheme 3.6.3.1 
Li et al. described the synthesis of analogous compounds from methyl anthranilate 144 
using microwave conditions, Scheme 3.6.3.2.161 Initial use of THF as the solvent in these 
reactions led to dimerization of the urea, so DMF and DMSO were screened, however this 
lead to the isolation of uncyclised product. It was thought that a nucleophilic solvent may 
be necessary in order to facilitate the elimination of methanol so a 1:1 DMSO:H2O solvent 
system was employed which lead to the formation of 148 with minimal dimerization. A 
range of compounds were synthesised probing substitution patterns, electron distribution 
and steric hindrance. A variety of N-3 aryl derivatives were all synthesised in good to 
excellent yields, however, N-3 alkyl analogues returned low yields. Steric hindrance did 
prove problematic as was evident in the use of 2,6-diisopropylphenylisocyanate where no 
product was formed. Overall this method was proved to be a rapid and green alternative 
to Willis’ synthesis. 
 
Scheme 3.6.3.2 
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3.7 N-1, N-3-Disubstituted quinazolinediones 
 
Section 1.2.3 and Section 1.2.4 highlight the relevance of N-1, N-3-disubstituted 
quinazolinediones in the development of prospective chemotherapeutic agents, 
specifically in the design of peptidomimetics for use as anti-cancer agents and also as new 
therapies in the fight against antibiotic resistance. 
 
3.7.1 Synthesis from anthranilate precursors 
 
While searching for potential immunosuppressive and anti-inflammatory agents Michne 
et al. described a method for synthesising N-1, N-3-disubstituted quinazolinediones, 
Scheme 3.7.1.1.162 Alkylation of 151 followed by the formation of the amide using 
methylamine gave 152. Reaction of 152 with phenyl chloroformate in the presence of 
sodium hydride followed by reduction gave 153 in a 51% overall yield.   
 
Scheme 3.7.1.1 
Although not the most conventional method it does provide a viable route to N-1, N-3-
disubstituted quinazolinediones. More commonly N-3-substituted quinazolinediones are 
prepared and the N-1 position is substituted using an alkylating/arylating agent in the 
presence of a base. These reactions usually give high to excellent yields and a range of 
nucleophiles can be used. Michne et al. also described this method for compounds of type 
153 as did Willis, Scheme 3.7.1.2.  
Chapter 3 | Quinazoline Chemical Introduction 
 
Page | 86  
 
 
Scheme 3.7.1.2 
 
3.8 Conclusion 
 
Quinazolines represent a family of compounds which possess extensive and diverse 
biological profiles and as a result have gained significant interest in the field of medicinal 
chemistry. As a result of this interest much research has been carried out into the 
development of efficient routes of synthesis. This interest has lead to the development of 
many prospective novel chemotherapeutic agents, perhaps the most pronounced in this 
area is the development of 4-anilinoquinazolines which are currently at the cutting edge 
of cancer chemotherapeutics. 
In contrast elaboration of the quinazoline-2,4-dione pharmacophore remains an 
underdeveloped demesne of the quinazoline family. Given the beseeching biological 
modes of action attributed to a range of quinazoline-2,4-diones, the development of novel 
synthetic routes as well as elaboration of the pharmacophore is imperative in order to 
advance this area of chemotherapeutics. 
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